Compare BioNano Genomics Inc (BNGO) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs W W Grainger Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while W W Grainger Inc trades at $1,305.49 (market cap $61.32B). The key difference: W W Grainger Inc is far larger — about 4489× BioNano Genomics Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | GWW | |
|---|---|---|
Market Cap | $13.66M | $61.32B |
Sector | Health | Technology |
52-Week High | $4.92 | $1.40K |
52-Week Low | $1.06 | $918.18 |
Enterprise Value | $16.26M | $63.53B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
W.W. Grainger (GWW) trades at $1,304.88, up 0.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised its full-year outlook. Revenue grew to $18.8 billion in 2026, with a net income margin of 9.92%. Analyst consensus is a 'Hold' with a $1,320 price target, though institutional sentiment is mixed amid high valuation multiples.
GWW's earnings momentum and market share gains support upside potential, but elevated P/E of 33.19 and bearish technicals pose near-term risks. Investors should weigh robust fundamentals against valuation concerns and macroeconomic pressures affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
